SEVENTH STAKEHOLDER EVENT ON BIOSIMILAR MEDICINAL PRODUCTS
BRUSSELS, 13 DECEMBER 2023, MANSHOLT ROOM CHARLEMAGNE BUILDING
HYBRID (LINK FOR PRE-REGISTRATION)
9H00 – 16H30 CET

DRAFT AGENDA

09.00 – 09.30 **Registration and welcome**

09.30 – 09.45 **Introductory note**

- Rainer Becker, Director SANTE D (Medical Products and Innovation), European Commission

09.45– 10.00 **Patient perspectives on biosimilars**

- Ljiljana Vukota, Secretary-General NGO "Everything for Her"

10.00 – 10.30 **The impact of biosimilar competition in Europe**

- Per Troein, VP, Strategic partners, IQVIA
- Max Newton, Global supplier & association relations, IQVIA

Interactive Q&A discussion with the audience

10.30 – 11.00 ***Coffee & networking break***

11.00 – 12.30 **Upcoming losses of exclusivity in the biologics pipeline:**
addressing the challenges and lack of biosimilar competition

Moderator: Petra Wilson, Managing Director Health Connect Partners

Interactive panel discussion

- Yannis Natsis, Director of the European Social Insurance Platform (ESIP)
- Julie Maréchal-Jamil, Director Biosimilars Policy and Science (Medicines for Europe)
- Prof. Dr. Wolf-Dieter Ludwig, Chair of the Drug Commission of the German Medical Association and Chair of the working group of pharmaceuticals in the Standing Committee of European Doctors (CPME)
- Dimitrios Athanasiou, Patient Representative, World Duchenne Organization BoD, Rare Diseases Greece Chair
- Steffen Thirstrup, Chief Medical Officer EMA

Interactive Q&A discussion with the audience

12.30 – 13.30 ***Networking lunch***

13.30 – 15.00 **Disparities in biosimilar uptake and access:**
opportunities across countries, regions and sectors

Chair: Johan Pontén, Senior Manager International Affairs TLV (SE)

Challenges and good practice examples in pricing, reimbursement and demand-side measures to enhance the uptake of biosimilar medicines

- Sabine Vogler, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG)

How the revision of the EU general pharmaceutical legislation will stimulate broader earlier market entry of biosimilar medicines

- Harald Mische, Deputy Head of DG SANTE D2 Unit (Medical Products: Quality, Safety, Innovation)

What regulators can do to enhance the uptake of biosimilars

- Esa Heinonen, Acting Chair of the HMA Biosimilar Working Group, Senior Advisor to Fimea

Challenges and opportunities for biosimilar uptake specific to the inpatient sector

- Despoina Makridaki, Director of Pharmaceutical Services in Sismanoglio-Amalia Fleming General Hospital of Attica and Member of the EAHP Board

Sharing of national best practices and challenges

- Chara Kani, National Pharmacist at the Organisation for the Provision of Health Services (EOPPY, EL)
- Agnieszka Beer, Department of Medicinal Policy and Pharmacy (Ministry of Health, PL)

Interactive Q&A discussion with the audience

15.00 – 15.15 ***Coffee & networking break***

15.15 – 16.15 **Product formulation and administration:**
consequences for patients, healthcare professionals and systems

Chair: Carlos Martin Saborido, Senior Advisor to the Directorate General of Common Portfolio NHS and Pharmacy Spanish Ministry of Health

Regulatory aspects of biosimilar formulation and administration

- René Anour, Head of National Scientific Advice Austrian Medicines & Medical Devices Agency (AGES), Chair of EMA Biosimilar Working Party

Biosimilar formulation and administration: Transformative Opportunities and Challenges

- Adrian van den Hoven, Director General Medicines for Europe

Role of pharmacists

- Ana Soldo, President Croatian Chamber of Pharmacists

Reinvesting biosimilar savings to the benefit of patient access and administration

- Bernard Duggan, Chief I Pharmacist HSE Medicines Management Programme

Interactive Q&A discussion with the audience

16.15 - 16.30 **Closing words**

* * * * * *